Techniques for Cardiac Resynchronization Therapy in Patients with Congenital Heart Disease

Frank J Zimmerman1, David Gamboa1

  • 1Advocate Children's Heart Institute, 4440 West 95th Street, Oak Lawn, IL 60453, USA.

PubMed

Insights

Cardiac resynchronization therapy (CRT) offers benefits for heart failure in congenital heart disease. This review examines CRT techniques and outcomes in complex conditions like single ventricle physiology.

Area of Science:

  • Cardiology
  • Pediatric Cardiology
  • Cardiac Electrophysiology

Background:

  • Congenital heart disease frequently involves cardiac conduction defects and necessitates ventricular pacing.
  • Cardiac resynchronization therapy (CRT) is increasingly explored as an adjunct for heart failure management in these patients.
  • Established guidelines for CRT in complex congenital heart disease are lacking.

Purpose of the Study:

  • To review the techniques and short-term outcomes of CRT in complex congenital heart disease.
  • To evaluate CRT's applicability in single ventricle physiology, systemic right ventricle, and subpulmonic right ventricle.
  • To provide insights into the current status of CRT for specific congenital heart anomalies.

Main Methods:

  • Literature review of studies reporting CRT techniques and outcomes.
  • Focus on complex congenital heart disease populations.
  • Analysis of short-term efficacy and procedural aspects.

Main Results:

  • CRT has demonstrated success as an adjunctive therapy for heart failure in congenital heart disease.
  • Specific techniques and challenges exist for CRT implantation in single ventricle and other complex anatomies.
  • Short-term outcomes suggest feasibility and potential benefit, but long-term data is limited.

Conclusions:

  • CRT is a viable option for select patients with congenital heart disease and heart failure.
  • Further research is needed to establish optimal techniques and long-term efficacy.
  • CRT may improve functional status and reduce heart failure burden in complex congenital heart disease.

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
15
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
11
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
14
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
17
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
16
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
12